Showing results (1-10 of 8) with videos related to
Sort By:
Pageof 1
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|February 1, 2024
Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney DiseaseJie-Jiu Lu, Tao-Tao LiuJournal of Clinical Pharmacology|January 20, 2022
Comparison of Vancomycin Clearance Between Augmented Renal Clearance and Normal Renal Function in Critically Ill Infants: A Population Pharmacokinetics StudyGuang-Ming Huang, Yue Qiu, Tao-Tao Liu, et al.European Journal of Drug Metabolism and Pharmacokinetics|September 22, 2019
Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese PopulationRen Zhang, Ming Chen, Tao-Tao Liu, et al.Drugs & Aging|May 8, 2023
Dosage Optimization of Digoxin in Older Patients with Heart Failure and Chronic Kidney Disease: A Population Pharmacokinetic AnalysisZhong-Qiu Lin, Ling Guo, Li-Min Zhang, et al.Journal of Clinical Pharmacy and Therapeutics|August 30, 2019
Development and comparison of population pharmacokinetic models of vancomycin in neurosurgical patients based on two different renal function markersLi Jing, Tao-Tao Liu, Qing Guo, et al.Journal of Clinical Pharmacy and Therapeutics|June 20, 2020
Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance childrenChun-Le Lv, Jie-Jiu Lu, Ming Chen, et al.European Journal of Drug Metabolism and Pharmacokinetics|April 19, 2020
A Population Pharmacokinetics Model for Vancomycin Dosage Optimization Based on Serum Cystatin CJie-Jiu Lu, Ming Chen, Chun-Le Lv, et al.Pharmacotherapy|October 23, 2024
Sex differences in LDL-C reduction response to evolocumab: A propensity score matching analysisYe-Qian He, Yu-Qing Wei, Guang-Ming Huang, et al.Pageof 1